Germline Warfare
By Ralph Brave,
The Nation
| 04. 07. 2003
A most remarkable event occurred in the weeks preceding the
June 2000 announcement of the completion of the first draft
of the human genome DNA code: One of the leaders of the genome
project publicly called for strict limits on what the scientific
community should be permitted to do with the human genetic blueprint
now in hand.
At a conference at MIT, Dr. Eric Lander, leader of the team
that decoded the largest portion of the genome, called the conference
to attention with this surprisingly stark suggestion:
Already, there are well-meaning discussions about improving
the human DNA. I find this somewhat hubristic myself. [The human
genome] has been 3.5 billion years in the making. We've been
able to read it for the last, oh, I don't know, year or so.
And we suddenly think we could write the story better? It's
very amusing.
There is the prospect that by changing things we might put
off aging, prevent cancer, improve memory. I find it a very
difficult question. For my own part, I would put an absolute
ban in place on...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...